Home » Healthcare » Dogs Vaccines Market

Dogs Vaccines Market By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Other Vaccine Types); By Disease Type (Canine Parvovirus, Canine Distemper, Canine Infectious Respiratory Disease Complex [CIRDC], Canine Leptospirosis, Canine Rabies, Other Diseases); By Route of Administration (Injectable Vaccines, Oral Vaccines, Other Routes); By Application (Veterinary Clinics, Animal Hospitals, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Dogs Vaccines Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-09-26
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Dogs Vaccines Market

Summary
Table Of Content
Request Free Sample

Market Overview:

The Global Dogs Vaccines Market size was valued at USD 1,293.59 million in 2018, increased to USD 2,094.34 million in 2024, and is anticipated to reach USD 3,603.25 million by 2032, at a CAGR of 6.53% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Dogs Vaccines Market Size 2024	USD 2,094.34 million
Dogs Vaccines Market, CAGR	6.53%
Dogs Vaccines Market Size 2032	USD 3,603.25 million

The global dogs vaccines market is shaped by leading companies including Zoetis Inc., Merck & Co., Inc. (Merck Animal Health), Boehringer Ingelheim GmbH, Elanco Animal Health, Ceva Santé Animale, and Virbac S.A. These players maintain strong positions through extensive portfolios covering core and non-core canine diseases, alongside global distribution networks and strategic R&D investments. Regionally, Asia Pacific emerged as the largest market in 2024 with 34% share, supported by rapid pet adoption and government-backed vaccination programs. North America followed with 27% share, driven by high healthcare spending and regulatory mandates, while Europe accounted for 19%, reflecting strong veterinary infrastructure and vaccination compliance across member states.

Dogs Vaccines Market size

Market Insights

The global dogs vaccines market was valued at USD 2,094.34 million in 2024 and is projected to reach USD 3,603.25 million by 2032, expanding at a CAGR of 6.53%.
Rising pet ownership, increasing humanization of dogs, and strict regulatory mandates for rabies vaccination are major drivers fueling consistent vaccine demand worldwide.
Market trends highlight the adoption of advanced formulations such as recombinant and combination vaccines, along with growing interest in oral and intranasal delivery methods for ease of administration.
The competitive landscape is dominated by global players including Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Ceva Santé Animale, and Virbac, which expand their reach through innovation, partnerships, and strong distribution networks.
Regionally, Asia Pacific led with 34% share in 2024, followed by North America at 27% and Europe at 19%, while live attenuated vaccines and canine parvovirus vaccines held the largest shares within product and disease segments.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Segmentation Analysis:

By Vaccine Type

The dogs vaccines market by vaccine type is dominated by live attenuated vaccines, accounting for the largest share in 2024 due to their strong efficacy and ability to induce long-lasting immunity. These vaccines are widely used against core diseases such as distemper and parvovirus, which require reliable protection. Inactivated vaccines follow, offering safer options for immunocompromised dogs, while recombinant vaccines are gaining attention for their advanced safety profiles. Other vaccine types, though smaller in share, address niche diseases. Rising pet ownership and awareness of preventive healthcare drive growth across all categories.

For instance, Zoetis distributed more than 12 million doses of Vanguard® live attenuated canine vaccines globally in 2023, covering core diseases including distemper and parvovirus.

By Disease Type

In terms of disease type, canine parvovirus vaccines held the dominant market share in 2024, supported by the high prevalence and severe mortality risk of the disease among unvaccinated puppies. Canine distemper vaccines follow closely, driven by global vaccination campaigns. Canine infectious respiratory disease complex (CIRDC) vaccines are gaining traction due to urbanization and rising kennel populations. Rabies vaccines remain a critical category due to mandatory regulations in many countries. Vaccines for leptospirosis and other diseases contribute to growth as veterinarians expand multi-disease protection programs for dogs.

For instance, Boehringer Ingelheim plays a significant role in global animal health, and in 2023, the company distributed 43.2 million rabies vaccine doses through its “STOP Rabies” initiative. This initiative supported immunization programs in countries where rabies is endemic.

By Route of Administration

The market by route of administration is led by injectable vaccines, which captured the largest share in 2024, reflecting their established safety, dosage accuracy, and wide acceptance by veterinarians. Oral vaccines are expanding at a faster pace, driven by ease of administration and stress reduction in pets. These are particularly appealing for mass vaccination campaigns and for dogs that resist injections. Other routes, such as intranasal delivery, hold a smaller but growing niche, especially for respiratory diseases. The preference for injectable formats persists due to proven clinical outcomes and veterinarian reliance on standardized methods.

Market Overview

Rising Pet Ownership and Humanization of Dogs

The global dogs vaccines market is driven strongly by increasing pet ownership, particularly in urban areas where companion animals are considered part of the family. The growing humanization of dogs has led to rising healthcare spending, with owners prioritizing preventive treatments such as vaccinations to ensure longer, healthier lives. According to pet industry reports, annual veterinary care expenditure has increased significantly, creating consistent demand for both core and non-core vaccines. Additionally, pet adoption initiatives and awareness campaigns by animal welfare organizations highlight the risks of infectious diseases, pushing vaccination rates higher. The rapid expansion of dog adoption across emerging economies further strengthens this trend.

For instance, in May 2023, Elanco secured a conditional license from the U.S. Department of Agriculture for a Canine Parvovirus Monoclonal Antibody to treat the disease in the U.S.

Regulatory Mandates and Disease Control Programs

Government regulations and international initiatives mandating vaccination for rabies and other canine diseases remain a key driver. Many countries enforce compulsory rabies vaccination, especially in regions where stray populations are high and zoonotic transmission poses risks to humans. These mandates not only create steady vaccine demand but also encourage manufacturers to expand their supply networks. International agencies, including the World Health Organization (WHO), support mass rabies elimination programs by targeting canine populations, directly boosting vaccine consumption. Furthermore, regional disease control campaigns against parvovirus, distemper, and leptospirosis promote higher coverage and improve vaccination infrastructure. The synergy between regulatory compliance and global health objectives ensures continuous growth for the market.

For instance, Merck Animal Health supplied over 10 million doses of Nobivac® rabies vaccines in 2023 to support government-led canine rabies elimination programs across Asia and Africa.

Advancements in Veterinary Vaccine Technologies

Ongoing advancements in biotechnology are shaping the dogs vaccines market by introducing safer, more effective, and targeted solutions. Recombinant vaccines and DNA-based vaccines offer improved efficacy with fewer side effects, attracting veterinarians and pet owners seeking modern alternatives. These innovations reduce risks associated with live attenuated strains and increase adoption rates for advanced formulations. Additionally, combination vaccines that protect against multiple diseases in a single dose are gaining popularity for their convenience and reduced clinical visits. Veterinary research institutes and pharmaceutical companies are investing heavily in R&D, resulting in a pipeline of next-generation products. This technological progress enhances disease management and aligns with rising demand for preventive healthcare.

Key Trends & Opportunities

Growth of Preventive Healthcare and Wellness Services

Preventive healthcare is becoming a central theme in the pet care industry, offering significant opportunities for the dogs vaccines market. Pet owners increasingly prefer proactive measures such as vaccination, parasite prevention, and wellness checkups to avoid costly treatments for advanced diseases. Veterinary clinics are bundling vaccination services with wellness packages, ensuring regular uptake. The trend is reinforced by insurance companies expanding coverage for preventive services, lowering out-of-pocket costs for owners. This focus on wellness strengthens market penetration for vaccines and encourages repeat visits, positioning preventive care as a consistent revenue stream for veterinary providers and pharmaceutical companies alike.

For instance, in the U.S., Banfield Pet Hospital provides preventive care to more than 3 million pets annually, primarily through its bundled Optimum Wellness Plans covering routine services like core canine vaccinations such as parvovirus, distemper, and rabies.

Expansion in Emerging Economies

Emerging markets in Asia Pacific, Latin America, and parts of Africa present significant opportunities due to growing awareness of canine health and rising disposable incomes. Pet adoption rates are climbing rapidly in urban centers, while governments are increasing investments in veterinary infrastructure. For example, regional initiatives to control rabies and zoonotic diseases are creating demand for large-scale vaccination programs. Local players and multinational companies are expanding their reach by setting up regional distribution networks and offering cost-effective vaccines tailored to local disease burdens. This trend positions emerging economies as high-growth regions with untapped market potential.

Rising Demand for Oral and Intranasal Vaccines

The preference for less invasive vaccine delivery methods is increasing, providing growth opportunities for oral and intranasal formulations. These options reduce stress for pets, improve compliance among owners, and simplify mass immunization efforts in shelters or large canine populations. Oral rabies vaccines, in particular, are gaining traction in wildlife and stray dog management programs, complementing traditional injectable solutions. Veterinary innovation in alternative routes of administration not only improves efficiency but also enhances accessibility for areas with limited veterinary resources. This trend will continue to expand as companies invest in developing user-friendly formulations for both developed and developing markets.

Key Challenges

High Cost of Advanced Vaccines and Veterinary Care

Despite the market’s growth, the high cost of advanced vaccines and veterinary services poses a barrier, particularly in low-income regions. Recombinant and multi-disease vaccines, while effective, are often priced higher than traditional formulations, limiting access for cost-sensitive pet owners. In many emerging economies, veterinary care infrastructure is underdeveloped, and out-of-pocket expenses discourage routine vaccination. This price barrier can restrict adoption and slow vaccination coverage, especially where awareness campaigns alone cannot offset financial constraints. Manufacturers face pressure to balance innovation with affordability to expand reach across diverse income groups.

Vaccine Hesitancy and Limited Awareness in Developing Regions

Vaccine hesitancy among dog owners, fueled by misinformation about side effects and low awareness of disease risks, remains a major challenge. In rural and developing areas, many pet owners are unaware of vaccination schedules or fail to prioritize preventive care. Additionally, cultural perceptions and lack of veterinary accessibility contribute to low immunization rates. This hesitancy undermines disease control programs, leaving canine populations vulnerable to outbreaks. Addressing this challenge requires targeted education campaigns, community-based veterinary outreach, and stronger collaboration between governments, NGOs, and vaccine manufacturers to build trust and increase compliance rates.

Regional Analysis

North America

North America held a 27% share of the global dogs vaccines market in 2024, with revenue at USD 571.36 million, rising from USD 358.77 million in 2018. The region is projected to reach USD 987.33 million by 2032, expanding at a CAGR of 6.6%. Growth is driven by advanced veterinary infrastructure, high pet ownership, and strong awareness of preventive healthcare. The U.S. dominates regional demand due to mandatory rabies vaccination laws and rising expenditure on companion animal health. Continuous innovation by veterinary pharmaceutical companies further strengthens market penetration, keeping North America a leading region globally.

Europe

Europe accounted for a 19% market share in 2024, with a market size of USD 381.42 million, up from USD 248.82 million in 2018. The region is expected to reach USD 598.56 million by 2032, registering a CAGR of 5.3%. Market growth is supported by strict regulatory frameworks, widespread awareness of zoonotic risks, and comprehensive veterinary healthcare services. Countries such as Germany, France, and the U.K. contribute significantly, owing to higher pet adoption rates. The EU’s animal welfare regulations and vaccination mandates enhance compliance, ensuring strong vaccine uptake across both core and non-core disease segments.

Asia Pacific

Asia Pacific dominated the market with a 34% share in 2024, valued at USD 957.88 million, up from USD 570.77 million in 2018. The market is forecasted to reach USD 1,747.59 million by 2032, growing at the highest CAGR of 7.3% among regions. Rising disposable incomes, growing urban pet adoption, and increasing focus on preventive care are driving rapid expansion. China, India, and Japan are key contributors due to large canine populations and government-backed rabies control programs. Expanding veterinary networks and entry of global vaccine manufacturers further accelerate growth, making Asia Pacific the most dynamic regional market.

Latin America

Latin America captured a 4% share of the market in 2024, with revenue reaching USD 99.79 million, rising from USD 62.40 million in 2018. By 2032, the market is projected to grow to USD 152.37 million, at a CAGR of 4.9%. Brazil and Mexico dominate the region due to their sizeable pet populations and growing veterinary services industry. Increasing awareness of canine diseases and vaccination campaigns by local governments are improving adoption rates. However, economic disparities and limited veterinary infrastructure in rural areas moderate overall market growth, keeping Latin America smaller compared to developed regions.

Middle East

The Middle East represented a 3% share in 2024, generating USD 52.00 million, up from USD 35.23 million in 2018. The market is projected to reach USD 75.05 million by 2032, advancing at a CAGR of 4.2%. Rising pet adoption in urban centers such as the UAE and Saudi Arabia supports demand, while regulatory initiatives for rabies control enhance market penetration. Despite a smaller base, the region shows steady adoption as disposable incomes rise and pet care services expand. However, lower awareness in rural communities continues to challenge widespread vaccination uptake across the Middle East.

Africa

Africa accounted for a 2% market share in 2024, with revenue at USD 31.90 million, increasing from USD 17.61 million in 2018. The market is forecasted to reach USD 42.35 million by 2032, at a CAGR of 3.1%, the slowest among regions. Growth is mainly supported by international initiatives focused on rabies eradication, given the continent’s high incidence of zoonotic transmission. South Africa leads the region, benefiting from better veterinary infrastructure compared to other countries. However, limited access to veterinary care, low awareness, and economic barriers restrict large-scale vaccine adoption, keeping Africa a relatively small market contributor.

Market Segmentations:

By Vaccine Type

Live Attenuated Vaccines
Inactivated Vaccines
Recombinant Vaccines
Other Vaccine Types

By Disease Type

Canine Parvovirus
Canine Distemper
Canine Infectious Respiratory Disease Complex (CIRDC)
Canine Leptospirosis
Canine Rabies
Other Diseases

By Route of Administration

Injectable Vaccines
Oral Vaccines
Other Routes

By Application

Veterinary Clinics
Animal Hospitals
Others

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- Spain
- Russia
- Belgium
- Netherlands
- Austria
- Sweden
- Poland
- Denmark
- Switzerland
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Thailand
- Indonesia
- Vietnam
- Malaysia
- Philippines
- Taiwan
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Peru
- Chile
- Colombia
- Rest of Latin America
Middle East
- UAE
- KSA
- Israel
- Turkey
- Iran
- Rest of Middle East
Africa
- Egypt
- Nigeria
- Algeria
- Morocco
- Rest of Africa

Competitive Landscape

The global dogs vaccines market is highly competitive, led by established players such as Zoetis Inc., Merck & Co., Inc. (Merck Animal Health), Boehringer Ingelheim GmbH, Elanco Animal Health, Ceva Santé Animale, Virbac S.A., Hipra Human Health, S.A., Vetoquinol S.A., Phibro Animal Health Corporation, and Indian Immunologicals Limited. These companies dominate through extensive product portfolios, global distribution networks, and consistent investment in R&D to introduce advanced vaccines, including recombinant and combination formulations. Strategic initiatives such as mergers, partnerships, and regional expansions strengthen their market presence, particularly in high-growth regions like Asia Pacific. Companies also focus on expanding manufacturing capacities to meet rising demand from veterinary clinics and hospitals. Furthermore, recent developments in oral and intranasal vaccines demonstrate growing innovation aimed at improving compliance and ease of administration. Competitive intensity remains high, with firms balancing innovation, affordability, and regulatory compliance to capture larger market shares while addressing disease control needs worldwide.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Zoetis Inc.
Merck & Co., Inc. (Merck Animal Health)
Boehringer Ingelheim GmbH
Elanco Animal Health
Ceva Santé Animale
Virbac S.A.
Hipra Human Health, S.A.
Vetoquinol S.A.
Phibro Animal Health Corporation
Indian Immunologicals Limited

Recent Developments

In March 2024, Zendal group introduced CSIC-developed vaccine against canine leishmaniasis, a recombinant vaccine to combat canine leishmaniasis, a parasite that causes skin ulcers to severe inflammation of the liver and spleen.
In June 2024, Merck & Co., Inc., introduced the NOBIVAC NXT Rabies portfolio in Canada, which includes NOBIVAC NXT Canine-3 Rabies and NOBIVAC NXT Feline-3 Rabies, as part of the company’s continued commitment to rabies prevention.
In January 2022, Boehringer Ingelheim collaborated with MabGenesis, a biopharmaceutical company, to discover novel monoclonal antibodies in canines.
In November 2021, Ceva created a new cryogenic storage facility in Monor by investing in its European vaccine production capacity to meet the rapidly growing demand for vaccines.

Report Coverage

The research report offers an in-depth analysis based on Vaccine Type, Disease Type, Route of Administration, Application and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The market will expand steadily with rising global pet adoption and ownership rates.
Preventive healthcare will remain a top priority, increasing routine vaccination uptake in dogs.
Recombinant and DNA-based vaccines will gain higher adoption due to safety and efficacy.
Oral and intranasal vaccines will grow as alternatives to injectable formats.
Veterinary clinics and hospitals will strengthen their role as primary distribution channels.
Regulatory mandates for rabies vaccination will sustain consistent global demand.
Asia Pacific will continue to lead growth, supported by urbanization and awareness programs.
North America and Europe will maintain strong shares due to advanced veterinary infrastructure.
Manufacturers will focus on combination vaccines that offer protection against multiple diseases.
Strategic collaborations and R&D investments will drive innovation and expand market competitiveness.

CHAPTER NO. 1: GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2: EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3: DOGS VACCINES MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by Product

CHAPTER NO. 4: KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Vaccine Type & Disease Type Revenue

CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Dogs Vaccines Market Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global Dogs Vaccines Market Export Revenue By Region

CHAPTER NO. 7: COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Dogs Vaccines Market: Company Market Share

7.2. Global Dogs Vaccines Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8: DOGS VACCINES MARKET – BY VACCINE TYPE SEGMENT ANALYSIS

8.1. Dogs Vaccines Market Overview by Vaccine Type Segment

8.1.1. Dogs Vaccines Market Revenue Share By Vaccine Type

8.2. Live Attenuated Vaccines

8.3. Inactivated Vaccines

8.4. Recombinant Vaccines

8.5. Other Vaccine Types

CHAPTER NO. 9: DOGS VACCINES MARKET – BY DISEASE TYPE SEGMENT ANALYSIS

9.1. Dogs Vaccines Market Overview by Disease Type Segment

9.1.1. Dogs Vaccines Market Revenue Share By Disease Type

9.2. Canine Parvovirus

9.3. Canine Distemper

9.4. Canine Infectious Respiratory Disease Complex (CIRDC)

9.5. Canine Leptospirosis

9.6. Canine Rabies

9.7. Other Diseases

CHAPTER NO. 10: DOGS VACCINES MARKET – BY ROUTE OF ADMINISTRATION SEGMENT ANALYSIS

10.1. Dogs Vaccines Market Overview by Route of Administration Segment

10.1.1. Dogs Vaccines Market Revenue Share By Route of Administration

10.2. Injectable Vaccines

10.3. Oral Vaccines

10.4. Other Routes

CHAPTER NO. 11: DOGS VACCINES MARKET – BY APPLICATION SEGMENT ANALYSIS

11.1. Dogs Vaccines Market Overview by Application Segment

11.1.1. Dogs Vaccines Market Revenue Share By Application

11.2. Veterinary Clinics

11.3. Animal Hospitals

11.4. Others

CHAPTER NO. 12: DOGS VACCINES MARKET – REGIONAL ANALYSIS

12.1. Dogs Vaccines Market Overview by Region Segment

12.1.1. Global Dogs Vaccines Market Revenue Share By Region

12.1.2. Region

12.1.3. Global Dogs Vaccines Market Revenue By Region

12.1.4. Vaccine Type

12.1.5. Global Dogs Vaccines Market Revenue By Vaccine Type

12.1.6. Disease Type

12.1.7. Global Dogs Vaccines Market Revenue By Disease Type

12.1.8. Route of Administration

12.1.9. Global Dogs Vaccines Market Revenue By Route of Administration

12.1.10. Application

12.1.11. Global Dogs Vaccines Market Revenue By Application

CHAPTER NO. 13: NORTH AMERICA DOGS VACCINES MARKET – COUNTRY ANALYSIS

13.1. North America Dogs Vaccines Market Overview by Country Segment

13.1.1. North America Dogs Vaccines Market Revenue Share By Region

13.2. North America

13.2.1. North America Dogs Vaccines Market Revenue By Country

13.2.2. Vaccine Type

13.2.3. North America Dogs Vaccines Market Revenue By Vaccine Type

13.2.4. Disease Type

13.2.5. North America Dogs Vaccines Market Revenue By Disease Type

13.2.6. Route of Administration

13.2.7. North America Dogs Vaccines Market Revenue By Route of Administration

13.2.8. Application

13.2.9. North America Dogs Vaccines Market Revenue By Application

13.3. U.S.

13.4. Canada

13.5. Mexico

CHAPTER NO. 14: EUROPE DOGS VACCINES MARKET – COUNTRY ANALYSIS

14.1. Europe Dogs Vaccines Market Overview by Country Segment

14.1.1. Europe Dogs Vaccines Market Revenue Share By Region

14.2. Europe

14.2.1. Europe Dogs Vaccines Market Revenue By Country

14.2.2. Vaccine Type

14.2.3. Europe Dogs Vaccines Market Revenue By Vaccine Type

14.2.4. Disease Type

14.2.5. Europe Dogs Vaccines Market Revenue By Disease Type

14.2.6. Route of Administration

14.2.7. Europe Dogs Vaccines Market Revenue By Route of Administration

14.2.8. Application

14.2.9. Europe Dogs Vaccines Market Revenue By Application

14.3. UK

14.4. France

14.5. Germany

14.6. Italy

14.7. Spain

14.8. Russia

14.9. Rest of Europe

CHAPTER NO. 15: ASIA PACIFIC DOGS VACCINES MARKET – COUNTRY ANALYSIS

15.1. Asia Pacific Dogs Vaccines Market Overview by Country Segment

15.1.1. Asia Pacific Dogs Vaccines Market Revenue Share By Region

15.2. Asia Pacific

15.2.1. Asia Pacific Dogs Vaccines Market Revenue By Country

15.2.2. Vaccine Type

15.2.3. Asia Pacific Dogs Vaccines Market Revenue By Vaccine Type

15.2.4. Disease Type

15.2.5. Asia Pacific Dogs Vaccines Market Revenue By Disease Type

15.2.6. Route of Administration

15.2.7. Asia Pacific Dogs Vaccines Market Revenue By Route of Administration

15.2.8. Application

15.2.9. Asia Pacific Dogs Vaccines Market Revenue By Application

15.3. China

15.4. Japan

15.5. South Korea

15.6. India

15.7. Australia

15.8. Southeast Asia

15.9. Rest of Asia Pacific

CHAPTER NO. 16: LATIN AMERICA DOGS VACCINES MARKET – COUNTRY ANALYSIS

16.1. Latin America Dogs Vaccines Market Overview by Country Segment

16.1.1. Latin America Dogs Vaccines Market Revenue Share By Region

16.2. Latin America

16.2.1. Latin America Dogs Vaccines Market Revenue By Country

16.2.2. Vaccine Type

16.2.3. Latin America Dogs Vaccines Market Revenue By Vaccine Type

16.2.4. Disease Type

16.2.5. Latin America Dogs Vaccines Market Revenue By Disease Type

16.2.6. Route of Administration

16.2.7. Latin America Dogs Vaccines Market Revenue By Route of Administration

16.2.8. Application

16.2.9. Latin America Dogs Vaccines Market Revenue By Application

16.3. Brazil

16.4. Argentina

16.5. Rest of Latin America

CHAPTER NO. 17: MIDDLE EAST DOGS VACCINES MARKET – COUNTRY ANALYSIS

17.1. Middle East Dogs Vaccines Market Overview by Country Segment

17.1.1. Middle East Dogs Vaccines Market Revenue Share By Region

17.2. Middle East

17.2.1. Middle East Dogs Vaccines Market Revenue By Country

17.2.2. Vaccine Type

17.2.3. Middle East Dogs Vaccines Market Revenue By Vaccine Type

17.2.4. Disease Type

17.2.5. Middle East Dogs Vaccines Market Revenue By Disease Type

17.2.6. Route of Administration

17.2.7. Middle East Dogs Vaccines Market Revenue By Route of Administration

17.2.8. Application

17.2.9. Middle East Dogs Vaccines Market Revenue By Application

17.3. GCC Countries

17.4. Israel

17.5. Turkey

17.6. Rest of Middle East

CHAPTER NO. 18: AFRICA DOGS VACCINES MARKET – COUNTRY ANALYSIS

18.1. Africa Dogs Vaccines Market Overview by Country Segment

18.1.1. Africa Dogs Vaccines Market Revenue Share By Region

18.2. Africa

18.2.1. Africa Dogs Vaccines Market Revenue By Country

18.2.2. Vaccine Type

18.2.3. Africa Dogs Vaccines Market Revenue By Vaccine Type

18.2.4. Disease Type

18.2.5. Africa Dogs Vaccines Market Revenue By Disease Type

18.2.6. Route of Administration

18.2.7. Africa Dogs Vaccines Market Revenue By Route of Administration

18.2.8. Application

18.2.9. Africa Dogs Vaccines Market Revenue By Application

18.3. South Africa

18.4. Egypt

18.5. Rest of Africa

CHAPTER NO. 19: COMPANY PROFILES

19.1. Zoetis Inc.

19.1.1. Company Overview

19.1.2. Product Portfolio

19.1.3. Financial Overview

19.1.4. Recent Developments

19.1.5. Growth Strategy

19.1.6. SWOT Analysis

19.2. Merck & Co., Inc. (Merck Animal Health)

19.3. Boehringer Ingelheim GmbH

19.4. Elanco Animal Health

19.5. Ceva Santé Animale

19.6. Virbac S.A.

19.7. Hipra Human Health, S.A.

19.8. Vetoquinol S.A.

19.9. Phibro Animal Health Corporation

19.10. Indian Immunologicals Limited

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions

What is the current market size for Global Dogs Vaccines market, and what is its projected size in 2032?

The market was valued at USD 2,094.34 million in 2024 and will reach USD 3,603.25 million by 2032.

At what Compound Annual Growth Rate is the Global Dogs Vaccines market projected to grow between 2025 and 2032?

The market is projected to grow at a CAGR of 6.53% during the forecast period.

Which Global Dogs Vaccines market segment held the largest share in 2024?

Live attenuated vaccines and canine parvovirus vaccines held the largest shares in 2024.

What are the primary factors fueling the growth of the Global Dogs Vaccines market?

Key drivers include rising pet ownership, regulatory mandates for rabies, and advancements in vaccine technology.

Who are the leading companies in the Global Dogs Vaccines market?

Major players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Ceva Santé Animale, and Virbac.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

Varicella Vaccine Market

The varicella vaccine market size was valued at USD 3.39 billion in 2024 and is anticipated to reach USD 5.53 billion by 2032, at a CAGR of 6.3 % during the forecast period.

Rehabilitation Robots Market

Rehabilitation Robots Market size was valued USD 1.52 billion in 2024 and is anticipated to reach USD 5.59 billion by 2032, at a CAGR of 17.7% during the forecast period.

Rehabilitation Chairs Market

Rehabilitation Chairs Market size was valued USD 1.47 billion in 2024 and is anticipated to reach USD 2.39 billion by 2032, at a CAGR of 6.24% during the forecast period.

Speech Analytics Market

The speech analytics market size was valued at USD 3.09 billion in 2024 and is anticipated to reach USD 11.29 billion by 2032, at a CAGR of 17.56 % during the forecast period.

Australia Sleep Apnea Devices Market

The Australia Sleep Apnea Devices Market size was valued at USD 36.77 million in 2018, reached USD 61.97 million in 2024, and is anticipated to reach USD 127.93 million by 2032, growing at a CAGR of 8.83% during the forecast period.

Wildlife Health Market

Wildlife Health market size was valued at USD 2.59 billion in 2024 and is projected to reach USD 5.04 billion by 2032, registering a CAGR of 8.7% during the forecast period.

Smart Orthopedic Implants Market

The Smart Orthopedic Implants market size was valued at USD 50.87 billion in 2024 and is projected to reach USD 179.87 billion by 2032, expanding at a CAGR of 17.1% during the forecast period.

Virtual PLC and Soft PLC in Pharmaceutical Market

Global Virtual PLC and Soft PLC in Pharmaceutical market size was valued at USD 149.2 million in 2018 and grew to USD 266.9 million in 2024. It is anticipated to reach USD 649.1 million by 2032, expanding at a CAGR of 11.90% during the forecast period.

U.S. Skincare Supplement Market

The U.S. Skin Supplements Market size was valued at USD 491.29 million in 2018 to USD 804.53 million in 2024 and is anticipated to reach USD 1,488.09 million by 2032, at a CAGR of 7.99% during the forecast period.

Europe Pharmaceutical Contract Sales Organizations Market

The Europe Pharmaceutical Contract Sales Organizations Market is projected to grow from USD 2,635.17 million in 2024 to an estimated USD 4,772.90 million by 2032, with a compound annual growth rate (CAGR) of 7.71% from 2024 to 2032.

Thyroid Ablation Devices Market

The thyroid ablation devices market size was valued at USD 228 million in 2024 and is anticipated to reach USD 464.4 million by 2032, at a CAGR of 9.3% during the forecast period.

Tendonitis Treatment Market

The Tendonitis Treatment Market size was valued at USD 219.15 billion in 2024 and is anticipated to reach USD 297.62 billion by 2032, at a CAGR of 3.9% during the forecast period (2024-2032).

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample